EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT

Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial.

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial

Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study

The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project

Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: the OPHELIA phase 2 study

Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and
pathological complete response (pCR) in HER2-positive early breast cancer (EBC):
An exploratory analysis of the PHERGain trial

ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria

The impact of decision tools during oncological consultation with lung cancer patients: a systematic-review within the i3LUNG project

Evaluation of HER2DX risk-score in residual disease (RD) from HER2-positive (HER2+) early breast cancer (EBC) patients (pts) following neoadjuvant trastuzumab and pertuzumab (HP)-based therapy: An exploratory analysis from the PHERGain trial

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

Evaluation of a Generative Artificial Intelligence (AI) and Natural Language Processing (NLP) tool to obtain clinical data from electronic health records (EHRs) versus manual data capture in Oncology Clinical Trials: The MIRROR study.